General Hepatology Update: Contemporary Management of Advanced Liver Diseases—From Metabolic Dysfunction–Associated Steatohepatitis Therapies to Decompensated Cirrhosis

Nov 08 2026
Convention Center: Bluebird Ballroom 2DEF
8:00 AM - 9:30 AM
Captured/recorded session Recorded
CE Credits CE Credits

Description

Join this comprehensive educational program designed to equip clinicians and advanced practice providers with practical, evidence-based approaches across the spectrum of advanced liver disease. Through 3 focused presentations, the program addresses the optimal use of newly approved metabolic dysfunction–associated steatohepatitis therapies; key updates in hepatocellular carcinoma surveillance and management; and contemporary strategies for caring for patients with decompensated cirrhosis. Speakers emphasize clinical decision-making, integration of noninvasive testing, multidisciplinary care, and translating recent advances into everyday practice for hepatologists and the broader liver care team.

Presentations

8:00 AM - 8:25 AM
Convention Center - Bluebird Ballroom 2DEF
Recorded session

Hepatocellular Carcinoma: Key Updates in Surveillance, Diagnosis, and Management

Sudha Kodali, MD, MSPH | Presenter
8:25 AM - 8:50 AM
Convention Center - Bluebird Ballroom 2DEF
Recorded session

Approved Metabolic Dysfunction–Associated Steatohepatitis Therapies: Which Treatment Should I Use—and When?

Meena B Bansal, MD, FAASLD | Presenter
8:50 AM - 9:15 AM
Convention Center - Bluebird Ballroom 2DEF
Recorded session

Management of Decompensated Cirrhosis: Practical Approaches and Evolving Strategies

Jennifer C Lai, MD, MBA | Presenter

Objectives

  • Review approved pharmacologic therapies for metabolic dysfunctionassociated steatohepatitis (MASH), and discuss patient selection, timing of therapy initiation, and sequencing of treatments.
  • Describe the integration of noninvasive testing and fibrosis staging into treatment decision-making for MASH.
  • Summarize recent advances in hepatocellular carcinoma (HCC) surveillance and early detection.
  • Review updates in systemic and locoregional treatment strategies for HCC, and multidisciplinary approaches to optimize patient outcomes.
  • Recognize key clinical features and complications of decompensated cirrhosis, and review evidence-based management of ascites, encephalopathy, variceal bleeding, and renal dysfunction as well as referral timing for transplant evaluation and palliative care integration.